Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...

For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

The game-changing weight loss jabs have ushered in a new era in the war on obesity, but have also been linked to other health ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment <li /> Combination of oral PL7737 ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

A new study found weight loss injections may help reduce the risk of dementia and stroke in people who are obese and have ...

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.

It gained approval for these patients in China in April, and the company announced today that it has begun clinical trials of the ... for their lead injectable obesity drug, which works similarly to ...

Fractyl Health offers a high-risk, high-reward setup with a near-term binary catalyst in the REMAIN-1 cohort data expected Q3 ...

Yet exercise can sometimes be deceptive. Years before starting Virta Health, while cofounding the real-estate company Trulia, ...